Forschung & Innovation
Publikationen
Clinical Impact of ACE-I/ARB for Conservatively Treated Patients with Moderate to Severe Mitral Regurgitation: A Single Center Observational Study.
PMU Autor*innen
Christian Datz, Bernhard Wernly
Alle Autor*innen
Robert Uzel, Raphael R Bruno, Christian Jung, Christian Lang, Hannes Hoi, Martin Grünbart, Christian Datz, Friedrich Hoppichler, Bernhard Wernly
Fachzeitschrift
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE
Kurzfassung
(1) Background: Mitral regurgitation (MR) is associated with increased mortality and frequent hospital admissions. Although mitral valve intervention offers improved clinical outcomes for MR, it is not feasible in many cases. Moreover, conservative therapeutic opportunities remain limited. The aim of this study was to evaluate the impact of ACE inhibitors and angiotensin receptor blockers (ACE-I/ARB) on elderly patients with moderate-to-severe MR and mildly reduced to preserved ejection fraction. (2) Methods: In total, 176 patients were included in our hypothesis-generating, single-center observational study. Hospitalization for heart failure and all-cause death have been defined as the combined 1-year primary endpoint. (3) Results: Patients treated with ACEI/ARB showed a lower risk for the combined endpoint of death and heart failure-related readmission (HR 0.52 95%CI 0.27-0.99; p = 0.046), even after adjustment for EUROScoreII and frailty (HR 0.52 95%CI 0.27-0.99; p = 0.049) (4) Conclusions: The use of an ACE-I/ARB in patients with moderate-to-severe MR and preserved to mildly reduced left-ventricular ejection fraction (LVEF) significantly associates with improved clinical outcome and might be indicated as a valuable therapeutic option in conservatively treated patients.
Keywords
THERAPY, MANAGEMENT, GUIDELINES, BURDEN, SECONDARY, VALVULAR HEART-DISEASE, ESC, Heart failure, Mitral regurgitation, Angiotensin receptor blocker, ACE inhibitor, HFmrEF